8 studies found for:    weill | Open Studies | "Liver Cirrhosis"
Show Display Options
Rank Status Study
1 Unknown  Effect of Large Volume Paracentesis on Fatigue in Cirrhosis
Conditions: Ascites;   Fatigue;   Cirrhosis
Intervention:
2 Unknown  The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Conditions: Hepatic Encephalopathy;   Hepatitis C;   Liver Cirrhosis
Intervention: Drug: Rifaximin (drug)
3 Unknown  Rifaximin Versus Lactulose in Renal Failure
Conditions: Liver Cirrhosis;   Renal Failure
Interventions: Drug: Rifaximin;   Drug: Lactulose
4 Unknown  Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)
Conditions: Spontaneous Bacterial Peritonitis;   Cirrhosis
Interventions: Drug: Standard Care;   Drug: Experimental
5 Recruiting Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
Conditions: Primary Biliary Cirrhosis;   PBC
Interventions: Drug: LUM001;   Drug: Placebo;   Drug: Ursodeoxycholic Acid
6 Recruiting Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium
Condition: Hepatic Fibrosis
Intervention: Procedure: MRI of liver
7 Recruiting Simtuzumab (GS-6624) in the Treatment of Liver Fibrosis in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab 75 mg;   Biological: Simtuzumab 125 mg;   Biological: Placebo
8 Recruiting Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC)
Condition: Primary Sclerosing Cholangitis (PSC)
Interventions: Biological: Simtuzumab;   Biological: Placebo

Indicates status has not been verified in more than two years